

17 February 2026

ASX ANNOUNCEMENT

\$10m exclusive global distribution agreement with EZZ Life Sciences (ASX:EZZ)

17 February 2026, Sydney, Australia. Aumake Limited ("Aumake" or "the Company") is pleased to announce that it has **formalised a strategic partnership with EZZ Life Sciences (ASX:EZZ)** via a 4-year exclusive global distribution agreement targeting minimum sales of \$10m.

Highlights

- The Company has well proven track record in the sales of high margin nutraceutical products, with more than \$2.1m in sales recorded since 2025, across wholesale B2B and B2C channels (\$1.6m and \$0.5m respectively).
- The agreement signed today, builds on this established sales channel through exclusive rights to a range of high value products from EZZ Life Sciences, including EZZ Glutathione Health Support, EZZ Vitality Boost, and EZZ Sleep, with scope to expand to further products.
- The agreement sets out minimum sales targets of \$2.5m per year each year for four years totalling \$10 million Australian dollars for the product range.
- The collaboration and distribution agreement includes a cooperative manufacturing model which ensures healthy margins, with sales and marketing driven through the Company's proven, B2C e-commerce platforms and B2B distribution network.
- The nutraceutical products segment is the highest margin segment within the Company's Nutritionals products channel, and this agreement will drive high margin sales in this segment.
- The distribution agreement is a global exclusive agreement for the products that are included and for the new products that will be co-developed to meet the demand in the China market.

Chairman, Dr Anthony Noble said: “The Company has continued to strengthen its commercial network in 2026, as we focus on building a trusted partnerships to drive growth. This expansion of our partnership with EZZ, which is highly aligned with our core strategy, comes on the back of a strong focus on compliance and the tighter commercial business processes that have been put in place in 2026, without which this deal would not have been possible. We believe this will be the first of many future collaborations that are now beginning to open to a refreshed and rejuvenated company. Successfully completing and executing this distribution partnership with EZZ and, we hope, far surpassing the minimum value in the contract, will serve as a proof point for other brands to collaborate with us in the Chinese e-commerce and B2B / retail distribution markets.”

“The company has sought shareholder approval to rebrand as *Xenitra* (ASX:XEN), reflecting our broader ambition in terms of both products, markets and value generation for shareholders, customers and consumers. We hope that these products will be some of the first to benefit from the *Xenitra* platform offering in 2026. The company is at a pivotal and exciting moment. We look forward to accelerating our growth and adding innovative strategies that deliver additional value to both the brands whom we distribute and to our consumers in China, which we will be announcing in the coming weeks.”



EZZ Chief Executive Officer, Mark Qin and AuMake Chairman Anthony Noble

Key Terms of the Agreement

Territory: Global
Exclusivity: Exclusive global distributor across all channels for the covered products
Minimum purchase commitments:
A\$10 million over the initial four-year term
Minimum A\$2.5 million per contract year
Brand & IP: EZZ retains full ownership and control of intellectual property and branding
Termination: Failure to meet either the aggregate minimum sales requirement or the annual minimum sales requirement shall result in the automatic termination of the worldwide exclusive rights granted.

About EZZ Life Science Holdings Limited

EZZ Life Science Holdings (ASX: EZZ), is a life science company with a mission to improve quality of life and human health. EZZ is passionate about investing in the future of consumer health through the development of e-commerce and distribution of high-quality products via omnichannel models across Australia, New Zealand, China and worldwide.

This release has been approved by the board of directors.

About Aumake:

Aumake Limited (Aumake or the company) (ASX: AUK) is a company with strong brand acceleration and sales capabilities, positioning it as a pioneer in delivering high quality brands and products from Australia and New Zealand to the Asia market.

Forward Looking Statements:

This announcement may contain forward-looking statements, including statements regarding: plans, strategies and objectives of management; anticipated revenue, products, and stores; operating costs; Chinese tourism; Governmental policies and preferences (both Australian and Chinese). Forward-looking statements can be identified by the use of terminology such as 'intend', 'aim', 'project', 'anticipate', 'estimate', 'plan', 'believe', 'expect', 'may', 'should', 'will', 'continue', 'annualised' or similar words. These statements discuss future expectations concerning the results of operations or financial condition, or condition or provide other forward-looking statements. These forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. Readers are cautioned not to put undue reliance on forward-looking statements. Except as required by applicable regulations or by law, the Group does not undertake any obligation to publicly update or review any forward-looking statements, whether as a result of new information or future events. Past performance cannot be relied on as a guide to future performance.